🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.615.172

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
27,17 (puede no estar actualizado)
Dividend yield
2,27% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 2 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/01/2017 152,09 153,72 151,77 152,87 +1,42% 1,28% 3.945.900
03/01/2017 147,86 151,00 147,12 150,73 +3,09% 2,62% 3.640.900
30/12/2016 147,63 148,75 145,62 146,21 -1,06% 2,12% 3.193.100
29/12/2016 147,37 148,69 147,37 147,78 +0,07% 0,90% 1.655.500
28/12/2016 148,63 149,15 147,36 147,67 -0,47% 1,20% 1.804.000
27/12/2016 147,77 150,11 147,77 148,36 +0,55% 1,58% 1.941.000
23/12/2016 146,35 147,73 146,24 147,55 +0,81% 1,02% 2.169.700
22/12/2016 146,31 146,61 145,12 146,36 +0,13% 1,02% 1.820.500
21/12/2016 147,07 147,63 145,70 146,17 -0,71% 1,31% 2.491.800
20/12/2016 146,82 147,99 146,47 147,22 -0,35% 1,04% 2.615.600
19/12/2016 149,75 150,35 147,21 147,74 -1,09% 2,10% 3.013.800
16/12/2016 150,92 151,21 148,81 149,37 -0,68% 1,59% 6.356.800
15/12/2016 149,18 150,47 148,78 150,39 +1,14% 1,13% 2.950.500
14/12/2016 148,16 149,55 147,42 148,69 +0,22% 1,44% 3.196.700
13/12/2016 146,81 149,97 146,55 148,37 +1,79% 2,33% 4.308.700
12/12/2016 142,92 146,04 142,79 145,76 +1,61% 2,27% 3.310.100
09/12/2016 141,50 144,58 141,00 143,45 +2,03% 2,53% 4.637.300
08/12/2016 140,83 141,10 138,83 140,59 -0,42% 1,61% 4.387.600
07/12/2016 143,52 143,88 139,66 141,19 -2,70% 2,94% 7.031.300
06/12/2016 145,80 145,99 144,28 145,11 -0,12% 1,17% 2.399.000
05/12/2016 145,45 146,37 143,72 145,29 +0,89% 1,82% 3.855.500
02/12/2016 142,29 144,91 141,50 144,01 +1,14% 2,40% 3.517.300
01/12/2016 144,24 144,24 142,14 142,39 -1,17% 1,46% 3.894.000
30/11/2016 145,70 146,32 144,07 144,07 -1,32% 1,54% 4.296.900
29/11/2016 145,36 146,79 145,31 146,00 +0,64% 1,02% 2.939.100
28/11/2016 145,25 145,92 144,50 145,07 -0,25% 0,98% 2.411.700
25/11/2016 145,22 146,00 144,76 145,43 +0,28% 0,85% 2.004.000
23/11/2016 142,94 145,17 142,84 145,03 +0,48% 1,63% 3.216.900
22/11/2016 146,82 146,95 142,82 144,33 -0,84% 2,81% 3.586.200
21/11/2016 145,99 146,17 145,11 145,55 +0,22% 0,73% 2.860.500